Available Technologies
# of Displayed Technologies: 4 / 4
Innovative Solutions for Acute Myeloid Leukemia: The Role of EGFL7
TS-064071 — EGFL7-centric technology for diagnosis, prognosis, and therapeutic strategies for hematologic malignancies.
The complex genetic landscape of Acute Myeloid Leukemia (AML), marked by chromosomal alterations and gene mutations, necessitates innovative approaches.
The Need
AML poses a significant challenge in the realm of hematologic malignancies, demanding both prognostic markers and novel treatments. Curr…
- College: College of Medicine (COM)
- Inventors: Dorrance, Adrienne; Garzon, Ramiro; Shen, Changxian
- Licensing Officer: Willson, Christopher
Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 —
CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need
More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
- College: College of Medicine (COM)
- Inventors: Ranganathan, Parvathi; Garzon, Ramiro
- Licensing Officer: He, Panqing
Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights …
- College: College of Medicine (COM)
- Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
- Licensing Officer: He, Panqing
Novel gapmers targeting HOXB-AS3 for Acute Myeloid Leukemia Treatment
TS-037979 — A novel treatment for acute meloid leukemia.
The expression of long non-coding RNAs (lncRNAs) in older adults with cytogenetically normal acute myeloid leukemia (CN-AML) is reported to have prognostic significance. lncRNA HOXB-AS3 was identified among the top up-regulated lncRNAs in NPM1-mutated CN-AML cases. Aberrant expression of HOX genes…
- College: College of Medicine (COM)
- Inventors: Garzon, Ramiro; Dorrance, Adrienne; Kauppinen, M.Sc., Ph.D., Sakari; Lee, Robert; Papaioannou, Dimitrios
- Licensing Officer: He, Panqing
